OC
VRTX icon

Opinicus Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Opinicus Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-673
Closed -$264K – 114
2025
Q3 		$264K Sell
673
-149
-18% -$62.3K 0.18% 96
2025
Q2 		$366K Buy
822
+3
+0.4% +$1.38K 0.28% 79
2025
Q1 		$397K Buy
+819
New +$382K 0.35% 72

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Opinicus Capital's VRTX Position: Q4 2025 in Review

Opinicus Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 673 shares — an estimated $264K sold.

Opinicus Capital first reported a position in VRTX in Q1 2025 and held it in 3 quarters. The position peaked at $397K in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Opinicus Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Opinicus Capital sold 673 Vertex Pharmaceuticals shares in Q4 2025, an estimated $264K.
  • Opinicus Capital first reported a position in Vertex Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Opinicus Capital's Vertex Pharmaceuticals position peaked at $397K in Q1 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Opinicus Capital's 13F filing for Q4 2025, filed 4 Feb 2026.